Twist Bioscience Enhances Genes Product Offering with Longer Genes and Offers Access to Its Application Programming Interface
“We are committed to continuously improving and expanding our product
lines to serve more and more of our customers’ needs,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist. “For the last year, we
have been supplying genes up to 5kb to Ginkgo Bioworks, and we are
confident in our ability to precisely manufacture scalable quantities of
these genes efficiently and clonal perfect. By offering long genes at
the disruptive price of
Twist Application Programming Interface (TAPI) Now Available for Gene Ordering
In addition to expanding its gene offering in length, Twist also announced the availability of the Twist Application Programming Interface (TAPI) for ordering synthetic genes, oligo pools and gene fragments. TAPI allows customers to integrate their internal software systems seamlessly with Twist’s design and business systems. Importantly, TAPI offers the functionality of the Twist online ordering portal with sequence synthesis analysis, codon optimization, download of plate maps and a comprehensive order tracking process from order placed to shipment received. These features can save time and resources for customers.
“Once available only to our largest customers, we have opened up our TAPI for all customers interested in designing and building genes and their pathways in one step, while at the same time transferring data directly and securely,” continued Dr. Leproust.
About Clonal Perfect Synthetic Genes
Applying its proprietary DNA synthesis technology, Twist manufactures strands of DNA up to five kilobases (5kb) in length. Customers order synthetic genes to conduct a wide range of research, including product development for the healthcare, agricultural, and industrial chemical industries as well as a multitude of applications within academic research. Virtually all research and development requires trial and error, and institutions require many variations of genes to find the DNA sequence that achieves their objectives. Twist offers perfectly clonal genes in either Twist or customer vectors. For more information please click here.
This press release contains forward-looking statements. All
statements other than statements of historical facts contained herein
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, Twist Bioscience’s expectations regarding ability to
increase market share and precisely manufacture scalable quantities of
perfect clonal DNA. Such forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the risks and
uncertainties of the ability to attract new customers and retain and
grow sales from existing customers; risks and uncertainties of rapidly
changing technologies and extensive competition in synthetic biology
could make the products